← USPTO Patent Applications

SINGLE-CHAIN MEDI1341 ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Application US20260078174A1 Kind: A1 Mar 19, 2026

Inventors

Matthias Magoola, Sarfaraz K. Niazi

Abstract

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

CPC Classifications

C07K 16/18 C07K 14/79 C07K 2317/622 C07K 2319/50

Filing Date

2024-09-16

Application No.

18886978